Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.38 |
| ▸ | ECE1 | P42892 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NPY2R | P49146 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5436150 | 0.88 | KDM4E (0.43) | ARGRM4KDM4CECE1P2RY14 | |
| SCHEMBL27693955 | 0.86 | OPRM1 (0.43) | ARGRM4KDM4CP2RY14CNR1 | |
| SCHEMBL5309570 | 0.85 | KDM4E (0.42) | KMT2A | |
| SCHEMBL14361090 | 0.83 | HPGD (0.45) | GRM4KDM4CMAPTL3MBTL1KMT2A | |
| SCHEMBL5430306 | 0.83 | CFD (0.45) | ARKDM4CSSTR4CNR1KMT2A | |
| SCHEMBL14360911 | 0.82 | L3MBTL1 (0.43) | L3MBTL1KMT2A | |
| SCHEMBL5306381 | 0.81 | CYP3A4 (0.45) | KDM4CMAPT | |
| SCHEMBL14360912 | 0.81 | TYK2 (0.47) | — | |
| SCHEMBL27713903 | 0.81 | KDM4C (0.43) | ARKDM4CSSTR4CNR1 | |
| SCHEMBL14360940 | 0.81 | ALDH1A1 (0.42) | GRM4MAPTL3MBTL1P2RY14KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265325-A1 | Nitro Indazole Derivatives | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265325-A1 | Nitro Indazole Derivatives | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265325-A1 | Nitro Indazole Derivatives | NOS3, CYP3A43, NOS2 | AR 1354/4885GRM4 1900/4885KDM4C 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.